Post-Launch Re-Pricing Likely the Focus of Chuikyo Leqembi Discussions

Chuikyo Drug Pricing Subcommittee Meeting on Oct. 4 Japan’s debate on the reimbursement policy of Leqembi (lecanemab), a newly approved Alzheimer’s disease (AD) drug by Eisai, will likely zero in on how to possibly re-price it after listing when it...read more